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pneumonitis in patients with non-small-cell 
lung cancer: a case series
Sarah Picard1,2*† , Desiree Goh1,2†, Ashley Tan2,3, Nisha Sikotra3, Eli Gabbay4,5 and Tim Clay2,6,7 
Abstract 
Background: Immunotherapy has become an efficacious option in the management of solid organ malignancies. 
Immune-related adverse events including pneumonitis are well described and may be particularly of concern in 
patients receiving immunotherapy for non-small-cell lung cancer.
Case presentations: In this paper, we describe three cases of immunotherapy-induced pneumonitis occurring in 
the management of lung malignancy. Our cases include a 54-year-old Caucasian woman with squamous cell lung 
cancer who was successfully rechallenged with immunotherapy after prior significant pneumonitis, a 65-year-old 
Caucasian man with metastatic squamous cell lung cancer who developed pneumonitis after multiple cycles of 
uneventful immunotherapy, and a 73-year-old Caucasian man with squamous cell lung cancer who developed early-
onset pneumonitis with rebound on steroid taper.
Conclusions: This case series has provided further insight into the presentation and risk factors for pneumonitis in 
patients with non-small-cell lung cancer. Each of the cases of immunotherapy-induced pneumonitis illustrates the 
different potential patterns that may arise when immunotherapy-induced pneumonitis develops. This case series 
provides key learning points that may assist physicians managing non-small-cell lung cancer with immunotherapy.
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Background
Immunotherapy is increasingly prescribed for solid organ 
and hematological malignancies, with striking improve-
ments in progression-free and overall survival in some 
cancers [1]. Immunotherapeutic drugs may cause life-
threatening immune-related adverse events (irAEs) 
including pneumonitis, complicating their use in lung 
cancer. Patients with advanced non-small-cell lung can-
cer (NSCLC) have a higher incidence of pneumonitis 
from immunotherapy (4.7% incidence) compared with 
the overall incidence of pneumonitis in patients with 
other solid organ malignancies receiving immunotherapy 
(2.92% incidence) [2]. In this paper, we describe three 
cases of immunotherapy-induced pneumonitis occurring 
in the management of lung malignancy.
Immune checkpoint inhibitors in routine clinical 
practice today target programmed death 1 (PD-1), pro-
grammed death ligand 1 (PD-L1), and cytotoxic T-lym-
phocyte-associated protein 4 (CTLA-4). These pathways 
are expressed in normal tissue as a mechanism to control 
the immune system, and they can become dysregulated 
in the tumor microenvironment [3]. Inhibition of these 
proteins with monoclonal antibodies causes upregula-
tion of the immune system [3, 4], allowing it to target 
and destroy cancer cells [2, 5]. However, T cells may 
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Pneumonitis is defined as focal or diffuse inflamma-
tion of the lung parenchyma [5, 7–9]. Pneumonitis may 
present asymptomatically and be incidentally found on 
computerized tomography (CT) scanning, or present 
symptomatically with cough, dyspnea, fatigue, or chest 
pain or clinical findings of progressive hypoxemia and 
respiratory failure [10–12]. Diagnosis is based on appro-
priate history and suggestive radiological findings on CT 
scanning. Definitive diagnosis requires a combination of 
bronchoalveolar lavage and/or a biopsy; however, these 
investigations are often impractical in an acutely unwell 
individual [10–12]. Suggestive radiological features 
include ground glass opacities, interstitial reticulation, or 
cryptogenic organizing pneumonia-like changes [8-10, 
12]. Pneumonitis caused by immunotherapy is graded 
using the Common Terminology Criteria for Adverse 
Events (CTCAE) severity scale, which ranges from grade 
1, asymptomatic, through to grade 5, where death occurs 
[2] (Table  1). Initial treatment is often empiric. Treat-
ment options include supportive therapy alone, oral or 
intravenous corticosteroids, cessation of immunotherapy, 
and, in refractory cases, the use of steroid-sparing agents 
as part of prolonged immunosuppression with mycophe-
nolate, infliximab, or cyclophosphamide [11, 13]. The 
outcome of patients who develop pneumonitis can range 
from complete resolution to death [12, 13].
Case presentations
We present three separate cases of immunotherapy-asso-
ciated pneumonitis seen at our institution, each of which 
we believe has important teaching points, in accordance 
with the CARE reporting checklist (Fig. 1).
Case 1: key point—rechallenge with immunotherapy 
after prior significant pneumonitis
A 54-year-old Caucasian woman with T3N3M0 stage 
IIIB squamous cell lung cancer was initially treated with 
induction chemotherapy (carboplatin/paclitaxel) fol-
lowed by chemoradiotherapy (cisplatin/etoposide) with 
curative intent. After 6 months, she relapsed in her pri-
mary tumor with increased fluorodeoxyglucose (FDG) 
uptake on her positron emission tomography (PET) scan. 
She was commenced on the PD-1 inhibitor nivolumab. 
She had a prior history of localized cervical cancer, hypo-
thyroidism, and a 6  pack-year smoking history. There 
were no other clear risk factors for pneumonitis. Follow-
ing her first dose of nivolumab, she immediately expe-
rienced facial flushing, fever, myalgia, and night sweats. 
Nine days following commencement of nivolumab, she 
was admitted to hospital with dyspnea.
On admission, her observations were oxygen satura-
tion 80% on room air, heart rate 116  beats per minute, 
and respiratory rate 20 breaths per minute. Her CT scan 
showed extensive patchy ground-glass infiltrates bilater-
ally (Fig. 2). She received supplemental oxygen via nasal 
prongs. She was commenced on intravenous methylpred-
nisolone 500 mg daily for 4 days followed by a prolonged 
taper on oral prednisolone over 3  weeks. She was con-
currently treated with intravenous piperacillin–tazobac-
tam and oral trimethoprim/sulfamethoxazole for 6  days 
to cover for potential concurrent infection. During her 
admission, other causes of pneumonitis were considered 
and excluded, and antibiotics ceased. The pneumonitis 
was grade 3 as per the Common Terminology Criteria for 
Adverse Events (CTCAE) version 5. Upon discharge, her 
Table 1 CTCAE grading of pneumonitis with suggested management as per ESMO guidelines
CTCAE Common Terminology Criteria for Adverse Events, ESMO European Society for Medical Oncology
Grade Clinical features Management
1 Asymptomatic Oral steroids—prednisone 1 mg/kg daily or equivalent with taper over 
4–6 weeks after recovery
Clinical and assessment every 2–3 days initially
Delay checkpoint inhibitor until equivalent daily dose of 10 mg oral predniso-
lone or less
2 Symptomatic—limiting instrumental activities of daily living As per grade 2
AND
Radiological assessment every 2–3 days initially
3 Severe symptoms—limiting self-care activities of daily living Hospital admission
High-dose intravenous corticosteroids (methylprednisolone 2–4 mg/kg/day or 
equivalent)
Cease immunotherapy permanently
Commence immunosuppression if no clinical or imaging improvement after 
2 days (such as infliximab, mycophenolate mofetil, cyclophosphamide)
Wean steroids slowly over 6 or more weeks
4 Life-threatening respiratory compromise As per grade 3
5 Death
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cardiorespiratory parameters were within normal range, 
and she had returned to her premorbid function.
Two months after treatment, the FDG-PET scan 
showed an initial partial metabolic response, with 
incomplete resolution of the changes due to pneumoni-
tis (Fig. 3). Over time, the pneumonitis settled, but there 
was cancer progression on FDG-PET after 5  months 
off nivolumab. On discussion between the patient and 
her treating team, nivolumab was reinstituted and 
treatment continued for a period of 18  months with a 
best response of stable disease. No further episodes of 
pneumonitis were observed. The patient subsequently 
died from cancer-associated venous thromboembolism 
unrelated to her prior immunotherapy.
Diagnosis Date 
Case 3 Immunotherapy 
Commenced
Case 3 Admission #1
Case 3 Admission #2
Case 3 Death
Case 2 Immunotherapy 
Commenced
Case 1 Immunotherapy 
Commenced
Case 1 Admission #1
Case 2 Admission #1
Case 2 Death
Case 1 Death
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28
Time (Months)
Immunotherapy Induced Pneumoni	s Key Event Timeline
Fig. 1  Timeline of key events
Fig. 2 Case 1—chest computed tomography (CT) revealing signs of 
pneumonitis
Fig. 3 Case 1—CT chest 2 months after commencement of 
pneumonitis treatment with incomplete resolution of pneumonitis 
changes
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Case 2: key points—pneumonitis occurring after multiple 
cycles of immunotherapy
A 65-year-old Caucasian man was diagnosed with meta-
static squamous cell carcinoma of the lung presenting 
with a large primary tumor, mediastinal nodal involve-
ment, and a malignant pleural effusion. He was initially 
treated with carboplatin and gemcitabine chemotherapy 
with partial response. On progression, he was treated 
with nivolumab with stable disease as best response. He 
had a 47 pack-year smoking history and no other sig-
nificant medical history. The significant smoking history 
and the subsequent risk of developing pneumonitis were 
considered, and the decision was made to proceed with 
immunotherapy and accept the associated risk given the 
potential benefit treatment would provide. He was com-
menced on nivolumab and was in his seventh month of 
treatment at the time of hospital admission. He presented 
3 days following administration of nivolumab with dysp-
nea, productive cough, lethargy, and decreased appetite.
On admission, he was hypoxemic with oxygen satura-
tion of 82% on room air, respiratory rate of 21 breaths 
per minute, heart rate of 80 beats per minutes, and tem-
perature of 38.7  °C. His CT chest showed widespread 
mixed ground glass and interstitial infiltrate, with pro-
gression of his malignancy (Figs.  4, 5). He was treated 
with intravenous methylprednisolone 1  g for 5  days. 
Mycophenolate was started on the fifth day of admis-
sion for a total of 3 days. He received concurrent intra-
venous antibiotic therapy with cefepime, meropenem, 
azithromycin, and trimethoprim/sulfamethoxazole. He 
continued to deteriorate, with progressively worsening 
hypoxemia, and was subsequently transitioned to end-
of-life care with grade 5 pneumonitis (Figs. 6, 7).
Fig. 4 Case 2—CT chest upper lobes revealing signs of pneumonitis, 
widespread mixed ground glass and interstitial infiltrate. There is 
progression of malignancy
Fig. 5 Case 2—CT chest lower lobes revealing signs of pneumonitis, 
widespread mixed ground glass and interstitial infiltrate. There is 
progression of malignancy
Fig. 6 Case 2—CT chest upper lobes with deterioration of 
pneumonitis despite treatment
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Case 3: key points—early‑onset pneumonitis with rebound 
on steroid taper
A 73-year-old Caucasian man with was diagnosed with 
T3N1M0 squamous cell carcinoma of the lung. He 
received treatment with chemoradiotherapy (weekly 
carboplatin/paclitaxel) with curative intent. An early 
FDG-PET scan showed partial response, and consolida-
tion immunotherapy durvalumab, a PD-L1 inhibitor, 
was commenced. He had a background of emphysema, 
cerebellar hematoma, cerebrovascular disease, coronary 
artery disease, hyperlipidemia, and hypothyroidism. He 
was an ex-smoker with a 75 pack-year history. The signif-
icant smoking history, emphysema, and recent radiother-
apy were considered as risk factors for the development 
of pneumonitis. After consideration, treatment pro-
ceeded, given the clear survival benefits demonstrated in 
the PACIFIC clinical trial [14]. Six days following the first 
dose of durvalumab, he developed dyspnea and a produc-
tive cough.
The patient was admitted to hospital. His initial obser-
vations showed oxygen saturation was 96% on room air 
with a respiratory rate of 20 breaths per minute, temper-
ature of 37  °C, and heart rate of 78 breaths per minute. 
His CT scan of the chest showed diffuse peribronchial 
ground-glass changes and a decrease in size of the lung 
cancer (Figs. 8, 9). He was admitted for 6 days and com-
menced on oral prednisolone 100  mg with a weaning 
regime and concurrent doxycycline for grade 3 pneumo-
nitis. The patient improved clinically, his observations 
were within normal cardiorespiratory parameters, and he 
was discharged on a prolonged steroid taper. The patient 
was reviewed by his respiratory physician and medical 
oncologist in clinic 3  weeks after discharge from hospi-
tal. Immunotherapy was not recommenced. A repeat 
CT scan showed marked resolution of the ground-glass 
changes, and he had returned to his premorbid function 
(Fig. 10).
One week after clinic review, the patient was readmit-
ted to hospital with increasing dyspnea and hemoptysis. 
He had been on corticosteroids for a period of 4  weeks 
and 4 days at this time. He was hypoxemic at 92% oxygen 
saturation on 4 L of oxygen per minute via nasal prongs, 
Fig. 7 Case 2—CT chest lower lobes with deterioration of 
pneumonitis despite treatment
Fig. 8 Case 3—CT chest before immunotherapy commenced
Fig. 9 Case 3—CT chest after immunotherapy given revealing signs 
of pneumonitis, diffuse peribronchial ground-glass changes. There is 
decrease in size of lung cancer
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had a respiratory rate of 20 breaths per minute and heart 
rate of 95 beats per minute, and was afebrile. A repeat CT 
scan of the chest showed recurrence of diffuse ground-
glass infiltrates, in keeping with acute pneumonitis, and 
no change in the size of the lung cancer (Fig. 11).
On readmission, oral corticosteroids were reesca-
lated to prednisolone 100  mg. The patient rapidly dete-
riorated, with worsening hypoxemia requiring admission 
to Intensive Care Unit (ICU). Immunosuppression was 
increased to pulse methylprednisolone 1  g daily with 
subsequent administration of intravenous cyclophos-
phamide. Broad antimicrobial therapy was administered 
to cover for concurrent infection (including ceftriaxone, 
piperacillin–tazobactam, meropenem, trimethoprim/sul-
famethoxazole, and azithromycin over the period of his 
admission). Respiratory support included supplemental 
oxygen via high-flow nasal prongs and periodic nonin-
vasive ventilation. Intubation and mechanical ventilation 
were deemed inappropriate in view of the guarded prog-
nosis and in discussion with the patient and his family. 
Despite maximal therapy, the patient’s condition deterio-
rated, and he died from grade 5 pneumonitis 18 days fol-
lowing admission.
Discussion and conclusion
Checkpoint inhibitor immunotherapy now enjoys wide-
spread use in cancer care. Severe adverse events with sin-
gle-agent PD-1 or PD-L1 inhibition are uncommon but 
well described—they can be unpredictable with regard to 
timing and severity and can result in significant morbid-
ity and, occasionally, mortality. With any presentation, 
irAEs must be considered in the differential diagnosis 
and acted on promptly. Pneumonitis remains a toxicity 
of particular concern for clinicians treating NSCLC with 
greatest incidence of immunotherapy-induced pneumo-
nitis [2]. In the current context, Coronavirus 19 infection 
also remains an important differential, and in jurisdic-
tions with community transmission, it is particularly 
important to exclude this diagnosis urgently.
The first case highlights that immunotherapy rechal-
lenge is possible but must occur after consideration of 
the therapeutic options and a discussion on risks and 
benefits. It is important for clinicians to highlight the 
uncertainty about the risk of further episodes of irAEs on 
immunotherapy rechallenge.
Our case series demonstrates:
1. Patients with underlying lung pathology or smok-
ing history are susceptible to developing high-grade 
pneumonitis.
2. Immunotherapy-induced pneumonitis can present at 
any time after commencement of immunotherapy.
3. The severity of immunotherapy-induced pneumoni-
tis does not appear to be correlated with the time-
frame of onset.
4. Immunotherapy-induced pneumonitis can flare or 
recur during the period of steroid taper.
5. Following careful consideration, immunotherapy 
rechallenge can occur for some patients with prior 
immunotherapy-induced pneumonitis. A careful dis-
cussion of the potential risks and benefits is required 
Fig. 10 Case 3—CT chest after treatment of pneumonitis with initial 
recovery
Fig. 11 Case 3—CT chest after relapse of pneumonitis. There is no 
change in size of lung cancer
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with the patient, given the uncertainty about the risk 
of further episodes of irAEs on immunity rechal-
lenge.
Nishinu et  al. identified that pneumonitis more com-
monly occurs in patients who have NSCLC 4.1% and 
renal cell carcinoma 4.1%, compared with patients with 
metastatic melanoma 1.6% [1]. Similarly, a meta-analysis 
of 16 randomized controlled trials found that the low-
est rates of pneumonitis were seen in patients treated 
for advanced melanoma (0.72%) and highest in patients 
treated for advanced NSCLC 4.7% [2]. Patients with 
NSCLC are more likely to have underlying lung disease 
such as chronic obstructive pulmonary disease (COPD), 
potentially increasing their susceptibility to pneumoni-
tis and/or to developing higher-grade pneumonitis [12]. 
A recent study by Suzuki et al. [15] indicates that lower 
lung static volumes such as with large thoracic tumors 
are associated with higher pneumonitis risk post-immu-
notherapy [16]. A past or current smoking history may 
also be a risk factor for the development of severe pneu-
monitis. Whether this is due to smoking itself or due to 
smoking-related lung diseases is unclear and perhaps dif-
ficult to discern, with two studies showing smoking on 
its own was not associated with an increased risk or inci-
dence of pneumonitis [17, 18].
Pneumonitis was demonstrated in this case series to 
present at variable time frames following administra-
tion of immunotherapy. The onset of pneumonitis from 
time of administration of immunotherapy can be vari-
able, which can complicate and delay the diagnosis [19]. 
In a study by Nishino et al., the median time to onset of 
immunotherapy-induced pneumonitis was 2.6  months, 
ranging from 0.5 to 11.5  months [13]. Pneumonitis 
must be considered among the differential diagnosis for 
patients presenting with early clinical deterioration and 
respiratory symptoms early in their treatment course. 
However, late onset of irAEs including pneumonitis can 
occur more than 90 days after cessation of immunother-
apy [20]. Delaunay et al. [9] found that the time to onset 
of pneumonitis was shorter in patients with NSCLC com-
pared with melanoma, with a median time to onset of 
2.1 and 5.2 months, respectively. In the same study, they 
found that the time to onset and severity of pneumonitis 
appeared to have no correlation [9]. As pneumonitis has 
a widely variable and unpredictable onset, pneumonitis 
must be carefully considered in the differential diagnosis 
of any patient who has received immunotherapy present-
ing with dyspnea, hypoxia, and/or cough, regardless of 
the time of onset.
Management of pneumonitis is based on the grade 
attributed by clinicians using the CTCAE definitions 
[19]. Treatment options include observation, oral or 
intravenous corticosteroids, cessation of immunotherapy, 
and, in refractory cases, the use of immunosuppression 
drugs including mycophenolate, infliximab, and cyclo-
phosphamide [11, 13]. Patients may require admission to 
hospital and respiratory support in a high-dependency or 
intensive care unit. The outcome of patients who develop 
pneumonitis can range from complete resolution to 
relapse, palliation, or death and is dependent on a multi-
tude of variables [12, 13]. The mainstay of therapy is cor-
ticosteroids; however, steroid-refractory cases challenge 
clinicians’ decisions regarding the appropriate dose, tim-
ing, and route of administration [19]. Steroid-sparing 
agents are often employed in the case of steroid refrac-
toriness; however, there appears to be limited data on the 
efficacy of these treatments [11]. The length of treatment 
and weaning regime implemented can also be a chal-
lenge with rebound toxicity on withdrawal of steroids 
[19]. As per the European Society for Medical Oncology 
guidelines, prednisolone should be weaned over 6 weeks 
minimum in grade 2 pneumonitis or minimum 8 weeks 
in grade 3 or 4 pneumonitis to prevent rebound of pneu-
monitis symptoms. However, despite a prolonged wean-
ing regime of immunosuppression following an episode 
of pneumonitis, pneumonitis may relapse without fur-
ther exposure to immunotherapy, with cases of chronic 
immune checkpoint pneumonitis as described by Naidoo 
et  al. [21]. This highlights that the biological effects of 
immunotherapy can persist for a long time, and relapse 
may occur following a prolonged wean.
The clinical decision to rechallenge with immunother-
apy is difficult and needs to be considered on an indi-
vidual basis. Invariably, the use of immunotherapy agents 
is currently occurring in the setting of advanced disease 
where the goal of prolonged cancer control is associated 
with improved survival. The mortality associated with 
the progression of cancer must be weighed up against 
the potentially life-threatening irAEs, and this can be a 
challenge for physicians with limited data available. The 
decision of whether to rechallenge with immunotherapy 
following high-grade toxicity is challenging for clinicians 
and patients. In general, it has been suggested that rede-
velopment of irAE after rechallenge is more common in 
patients with higher-grade irAE (grade 3 or 4). Santini 
et  al. [22] recommend avoiding rechallenging patients 
who required hospitalization for their initial irAE, as 
the recurrence/new rate of irAE’s was up to 87% in these 
patients. Interestingly, in a study of 93 patients who were 
rechallenged with immunotherapy for a range of different 
irAEs, the recurrence of new irAE was not more severe 
than the original event [23].
We believe that this case series has provided further 
insight into the presentation and risk factors for pneu-
monitis in patients with NSCLC. Each of the cases of 
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immunotherapy-induced pneumonitis illustrates the 
different potential patterns that may arise when immu-
notherapy-induced pneumonitis develops. Given the var-
iable onset and severity of pneumonitis, we recommend 
that immunotherapy-induced pneumonitis must always 
be considered as a differential, regardless of the time of 
onset. Special consideration should be given to patients 
with underlying lung disease or a significant smoking his-
tory, given the higher risk of mortality. The decision to 
rechallenge patients, while difficult, is possible. Early ini-
tiation and perhaps prolonged immunosuppressive ther-
apy may be required to optimize patient outcomes.
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